Study conduct in groups [Design Issues]

posted by ElMaestro  – Denmark, 2015-02-02 09:21 (4164 d 13:23 ago) – Posting: # 14347
Views: 29,794

Hi Smitha,

❝ If a Bioequivalence study has to be conducted in 2 groups (say 20 volunteers each), does the FDA or EMA require that all 40 volunteers be recruited into the study before Group 1 Period 1 dosing? :confused:


That's an interesting question. At least, I never gave it any thought, but of course that doesn't mean much.
If I get you right you are asking if you you need 40 signed ICF's before dosing your first subject. No guideline discusses it, I think.

I can't offer an answer, but I think I would play it safe. In a trial with 20 subject and 2 backups you would ordinarily have all 22 ICF's signed before the first subject is dosed. If the backups are needed the trial is in a sense having two groups, right? Only the second group is rather small, but in a sense it serves the same purposes: getting the desired number of subjects.
Also if you start a study when 20 ICFs are available and you cannot execute group 2 because you for some reason are running out of eligibles then all manners of GCP hell could ensue. Thus, I am leaning towards treating 20+20 like 20+2.

This is just one opinion and not a very qualified one. I hope others will chime in as I believe there might also be arguments for doing it the other way. So I will go make some popcorn and will watch this thread with interest.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
366 visitors (0 registered, 366 guests [including 25 identified bots]).
Forum time: 23:44 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5